サマリー

北米の急性リンパ球/リンパ芽球性白血病（ALL）診断薬市場は、2023年から2030年の予測期間において7.6%の大幅なCAGRを記録すると予測されます。この新しい市場レポートは、歴史的な年2020年のデータを含み、計算の基準年は2021年で、予測期間は2023年から2030年です
市場セグメンテーション
北米の急性リンパ性／リンパ芽球性白血病（ALL）診断薬市場、製品タイプ（機器および消耗品・アクセサリー）、検査タイプ（画像検査、生検、血液検査、その他）、癌タイプ（B細胞リンパ芽球性白血病／リンパ腫、T細胞リンパ芽球性白血病）別、年齢層（21歳未満、21～29歳、30～65歳、65歳以上）、性別（男性、女性）、エンドユーザー（病院、提携研究所、独立診断所、画像診断センター、がん研究機関、その他）、流通チャネル（直接入札、小売販売）、国（U．S.,国（米国、カナダ、メキシコ）産業動向と2030年までの予測
北米の急性リンパ性／リンパ芽球性白血病（ALL）診断薬市場の成長に寄与する主な要因として、以下のものが挙げられます：

- 白血病癌の有病率・発症率の上昇
- がん診断・治療のための医療費負担の増加
市場のプレーヤー：

北米の急性リンパ球/リンパ芽球性白血病（ALL）診断薬市場で事業を展開している主な企業には、以下のようなものがあります：

- F. ホフマン・ラ・ロシュ社
- サーモフィッシャーサイエンティフィック（株
- QIAGEN
- アボット
- シーメンス・メディカル・ソリューションズUSA, Inc.
- メルクKGaA
- ホロジック社
- ビオメリューSA
- アジレント・テクノロジー株式会社（Agilent Technologies, Inc.
- ディアソリン S.p.A.
- イルミナ社
- ミリアド・ジェネティクス社
- クエスト・ダイアグノスティックス・インコーポレイテッド
- バイオ・ラッド・ラボラトリーズ・インク
- Koninklijke Philips N.V.
- ビーディー
- エグザクト・サイエンス・コーポレーション
- タイムメディカルホールディング
- マイケルソン・ダイアグノスティックス株式会社
- ミンファウンドメディカルシステムズ株式会社

ページTOPに戻る

目次

TABLE OF CONTENTS
1 INTRODUCTION 54
1.1 OBJECTIVES OF THE STUDY 54
1.2 MARKET DEFINITION 54
1.3 OVERVIEW OF NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET 54
1.4 LIMITATIONS 56
1.5 MARKETS COVERED 57
2 MARKET SEGMENTATION 60
2.1 MARKETS COVERED 60
2.2 GEOGRAPHICAL SCOPE 61
2.3 YEARS CONSIDERED FOR THE STUDY 62
2.4 CURRENCY AND PRICING 62
2.5 DBMR TRIPOD DATA VALIDATION MODEL 63
2.6 MULTIVARIATE MODELLING 66
2.7 PRODUCT TYPE LIFELINE CURVE 66
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 67
2.9 DBMR MARKET POSITION GRID 68
2.10 MARKET TESTING TYPE COVERAGE GRID 70
2.11 VENDOR SHARE ANALYSIS 71
2.12 SECONDARY SOURCES 72
2.13 ASSUMPTIONS 72
3 EXECUTIVE SUMMARY 73
4 PREMIUM INSIGHTS 76
4.1 PESTEL ANALYSIS 77
4.2 PORTER’S FIVE FORCES 78
4.3 INDUSTRY INSIGHTS 79
5 EPIDEMIOLOGY 81
6 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, REGULATIONS 82
7 MARKET OVERVIEW 85
7.1 DRIVERS 87
7.1.1 NOVEL TECHNOLOGICAL ADVANCEMENTS IN LEUKEMIA DIAGNOSTICS 87
7.1.2 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 87
7.1.3 INCREASE IN AWARENESS REGARDING LEUKEMIA CANCER 88
7.1.4 GROWING PREVALENCE OF LEUKEMIA CANCER 88
7.2 RESTRAINTS 90
7.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF LEUKEMIA DIAGNOSTIC PRODUCTS 90
7.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF LEUKEMIA 91
7.3 OPPORTUNITIES 91
7.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR LEUKEMIA 91
7.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 92
7.3.3 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 92
7.4 CHALLENGES 93
7.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 93
7.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 94
8 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE 95
8.1 OVERVIEW 96
8.2 INSTRUMENTS 99
8.2.1 BIOPSY INSTRUMENTS 100
8.2.1.1 BONE MARROW BIOPSY 100
8.2.1.2 NEEDLE BIOPSY 100
8.2.1.3 SURGEON BIOPSY 101
8.2.1.4 OTHERS 101
8.2.2 PATHOLOGY-BASED INSTRUMENTS 101
8.2.2.1 PCR INSTRUMENTS 101
8.2.2.2 SLIDE STAINING SYSTEMS 101
8.2.2.3 TISSUE PROCESSING SYSTEMS 101
8.2.2.4 CELL PROCESSORS 102
8.2.2.5 OTHER PATHOLOGY-BASED INSTRUMENTS 102
8.2.3 IMAGING INSTRUMENTS 102
8.2.3.1 ULTRASOUND SYSTEMS 102
8.2.3.2 CT SYSTEMS 102
8.2.3.3 MRI SYSTEMS 102
8.2.3.4 OTHERS 103
8.2.4 OTHERS 103
8.3 CONSUMABLES & ACCESSORIES 103
8.3.1 KITS 104
8.3.1.1 PCR KITS 104
8.3.1.2 DNA POLYMERASE KITS 104
8.3.1.3 NUCLEIC ACID ISOLATION KITS 104
8.3.1.4 OTHERS 105
8.3.2 REAGENTS 105
8.3.2.1 ASSAYS 105
8.3.2.2 BUFFERS 105
8.3.2.3 PRIMERS 105
8.3.2.4 OTHERS 105
8.3.3 PROBES 106
8.3.4 OTHER CONSUMABLES 106
9 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE 107
9.1 OVERVIEW 108
9.2 BIOPSY 111
9.2.1 BONE MARROW BIOPSY 112
9.2.2 NEEDLE BIOPSY 112
9.2.3 SURGEON BIOPSY 112
9.2.4 OTHERS 112
9.3 BLOOD TEST 113
9.3.1 BLOOD CHEMISTRY TESTS 114
9.3.2 COMPLETE BLOOD COUNT (CBC) 114
9.3.3 OTHERS 114
9.4 IMAGING TEST 114
9.4.1 COMPUTED TOMOGRAPHY (CT) SCAN 115
9.4.2 MRI 115
9.4.3 POSITRON EMISSION TOMOHRAPHY (PET) SCAN 116
9.4.4 OTHERS 116
9.5 OTHERS 116
10 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE 117
10.1 OVERVIEW 118
10.2 B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA 121
10.2.1 EARLY PRE-B ALL 122
10.2.2 COMMON ALL 122
10.2.3 PRE-B ALL 122
10.2.4 MATURE B-CELL ALL 122
10.3 T-CELL LYMPHOBLASTIC LEUKEMIA 122
10.3.1 PRE-T ALL 123
10.3.2 MATURE T-CELL ALL 123
11 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY AGE GROUP 124
11.1 OVERVIEW 125
11.2 BELOW 21 128
11.3 21-29 129
11.4 30-65 130
11.5 65 AND ABOVE 131
12 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY GENDER 132
12.1 OVERVIEW 133
12.2 MALE 136
12.3 FEMALE 137
13 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY END USER 138
13.1 OVERVIEW 139
13.2 HOSPITALS 142
13.3 ASSOCIATED LABS 142
13.4 INDEPENDENT DIAGNOSTIC LABORATORIES 143
13.5 DIAGNOSTIC IMAGING CENTERS 144
13.6 CANCER RESEARCH INSTITUTES 144
13.7 OTHERS 145
14 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 146
14.1 OVERVIEW 147
14.2 DIRECT TENDER 150
14.3 RETAIL SALES 151
15 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION 152
15.1 NORTH AMERICA 153
15.1.1 U.S. 165
15.1.2 CANADA 171
15.1.3 MEXICO 177
16 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, COMPANY LANDSCAPE 183
16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 183
17 SWOT ANALYSIS 184
18 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET 185
18.1 F. HOFFMANN-LA ROCHE LTD. 185
18.1.1 COMPANY SNAPSHOT 185
18.1.2 REVENUE ANALYSIS 185
18.1.3 COMPANY SHARE ANALYSIS 186
18.1.4 PRODUCT PORTFOLIO 186
18.1.5 RECENT DEVELOPMENT 186
18.2 THERMO FISHER SCIENTIFIC INC. 187
18.2.1 COMPANY SNAPSHOT 187
18.2.2 REVENUE ANALYSIS 187
18.2.3 COMPANY SHARE ANALYSIS 188
18.2.4 PRODUCT PORTFOLIO 188
18.2.5 RECENT DEVELOPMENT 188
18.3 QIAGEN 189
18.3.1 COMPANY SNAPSHOT 189
18.3.2 REVENUE ANALYSIS 189
18.3.3 COMPANY SHARE ANALYSIS 190
18.3.4 PRODUCT PORTFOLIO 190
18.3.5 RECENT DEVELOPMENT 190
18.4 ABBOTT 191
18.4.1 COMPANY SNAPSHOT 191
18.4.2 REVENUE ANALYSIS 191
18.4.3 COMPANY SHARE ANALYSIS 192
18.4.4 PRODUCT PORTFOLIO 192
18.4.5 RECENT DEVELOPMENT 192
18.5 SIEMENS MEDICAL SOLUTIONS USA, INC. 193
18.5.1 COMPANY SNAPSHOT 193
18.5.2 REVENUE ANALYSIS 193
18.5.3 COMPANY SHARE ANALYSIS 194
18.5.4 PRODUCT PORTFOLIO 194
18.5.5 RECENT DEVELOPMENT 194
18.6 MERCK KGAA 195
18.6.1 COMPANY SNAPSHOT 195
18.6.2 REVENUE ANALYSIS 195
18.6.3 PRODUCT PORTFOLIO 196
18.6.4 RECENT DEVELOPMENT 196
18.7 HOLOGIC INC. 197
18.7.1 COMPANY SNAPSHOT 197
18.7.2 REVENUE ANALYSIS 197
18.7.3 PRODUCT PORTFOLIO 198
18.7.4 RECENT DEVELOPMENT 198
18.8 AGILENT TECHNOLOGIES, INC. 199
18.8.1 COMPANY SNAPSHOT 199
18.8.2 REVENUE ANALYSIS 199
18.8.3 PRODUCT PORTFOLIO 200
18.8.4 RECENT DEVELOPMENT 200
18.9 BD 201
18.9.1 COMPANY SNAPSHOT 201
18.9.2 REVENUE ANALYSIS 201
18.9.3 PRODUCT PORTFOLIO 202
18.9.4 RECENT DEVELOPMENT 202
18.10 BIOMÉRIEUX SA 203
18.10.1 COMPANY SNAPSHOT 203
18.10.2 REVENUE ANALYSIS 203
18.10.3 PRODUCT PORTFOLIO 204
18.10.4 RECENT DEVELOPMENTS 204
18.11 BIO-RAD LABORATORIES, INC. 205
18.11.1 COMPANY SNAPSHOT 205
18.11.2 REVENUE ANALYSIS 205
18.11.3 PRODUCT PORTFOLIO 206
18.11.4 RECENT DEVELOPMENT 206
18.12 DIASORIN S.P.A. 207
18.12.1 COMPANY SNAPSHOT 207
18.12.2 REVENUE ANALYSIS 207
18.12.3 PRODUCT PORTFOLIO 208
18.12.4 RECENT DEVELOPMENTS 208
18.13 EXACT SCIENCE CORPORATION 209
18.13.1 COMPANY SNAPSHOT 209
18.13.2 REVENUE ANALYSIS 209
18.13.3 PRODUCT PORTFOLIO 210
18.13.4 RECENT DEVELOPMENT 210
18.14 ILLUMINA, INC. 211
18.14.1 COMPANY SNAPSHOT 211
18.14.2 REVENUE ANALYSIS 211
18.14.3 PRODUCT PORTFOLIO 212
18.14.4 RECENT DEVELOPMENT 212
18.15 KONINKLIJKE PHILIPS N.V. 213
18.15.1 COMPANY SNAPSHOT 213
18.15.2 REVENUE ANALYSIS 213
18.15.3 PRODUCT PORTFOLIO 214
18.15.4 RECENT DEVELOPMENT 214
18.16 MEDONICA CO. LTD 215
18.16.1 COMPANY SNAPSHOT 215
18.16.2 PRODUCT PORTFOLIO 215
18.16.3 RECENT DEVELOPMENT 215
18.17 MICHAEL DIAGNOSTICS LTD 216
18.17.1 COMPANY SNAPSHOT 216
18.17.2 PRODUCT PORTFOLIO 216
18.17.3 RECENT DEVELOPMENT 216
18.18 MINFOUND MEDICAL SYSTEMS CO., LTD 217
18.18.1 COMPANY SNAPSHOT 217
18.18.2 PRODUCT PORTFOLIO 217
18.18.3 RECENT DEVELOPMENT 217
18.19 MYRIAD GENETICS, INC. 218
18.19.1 COMPANY SNAPSHOT 218
18.19.2 REVENUE ANALYSIS 218
18.19.3 PRODUCT PORTFOLIO 219
18.19.4 RECENT DEVELOPMENT 219
18.20 PLEXBIO 220
18.20.1 COMPANY SNAPSHOT 220
18.20.2 PRODUCT PORTFOLIO 220
18.20.3 RECENT DEVELOPMENTS 220
18.21 QUEST DIAGNOSTICS INCORPORATED 221
18.21.1 COMPANY SNAPSHOT 221
18.21.2 REVENUE ANALYSIS 221
18.21.3 PRODUCT PORTFOLIO 222
18.21.4 RECENT DEVELOPMENTS 222
18.22 STERNMED GMBH 223
18.22.1 COMPANY SNAPSHOT 223
18.22.2 PRODUCT PORTFOLIO 223
18.22.3 RECENT DEVELOPMENTS 223
18.23 TIME MEDICAL HOLDING 224
18.23.1 COMPANY SNAPSHOT 224
18.23.2 PRODUCT PORTFOLIO 224
18.23.3 RECENT DEVELOPMENT 224
19 QUESTIONNAIRE 225
20 RELATED REPORTS 229

ページTOPに戻る

図表リスト

LIST OF TABLES
TABLE 1 APPROVED DIAGNOSTICS OF LEUKEMIA 59
TABLE 2 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 66
TABLE 3 NORTH AMERICA INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 67
TABLE 4 NORTH AMERICA INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 68
TABLE 5 NORTH AMERICA BIOPSY INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 68
TABLE 6 NORTH AMERICA PATHOLOGY-BASED INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 69
TABLE 7 NORTH AMERICA IMAGING INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 70
TABLE 8 NORTH AMERICA CONSUMABLES & ACCESSORIES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 71
TABLE 9 NORTH AMERICA CONSUMABLES & ACCESSORIES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 72
TABLE 10 NORTH AMERICA KITS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 72
TABLE 11 NORTH AMERICA REAGENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 73
TABLE 12 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 78
TABLE 13 NORTH AMERICA BIOPSY IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 79
TABLE 14 NORTH AMERICA BIOPSY IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 80
TABLE 15 NORTH AMERICA BLOOD TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 81
TABLE 16 NORTH AMERICA BLOOD TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 82
TABLE 17 NORTH AMERICA IMAGING TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 83
TABLE 18 NORTH AMERICA IMAGING TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 83
TABLE 19 NORTH AMERICA OTHERS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 84
TABLE 20 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 88
TABLE 21 NORTH AMERICA B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 89
TABLE 22 NORTH AMERICA B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 90
TABLE 23 NORTH AMERICA T-CELL LYMPHOBLASTIC LEUKEMIA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 91
TABLE 24 NORTH AMERICA T-CELL LYMPHOBLASTIC LEUKEMIA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 91
TABLE 25 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 95
TABLE 26 NORTH AMERICA BELOW 21 IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 96
TABLE 27 NORTH AMERICA 21-29 IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 97
TABLE 28 NORTH AMERICA 30-65 IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 98
TABLE 29 NORTH AMERICA 65 AND ABOVE IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 99
TABLE 30 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 103
TABLE 31 NORTH AMERICA MALE IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 104
TABLE 32 NORTH AMERICA FEMALE IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 105
TABLE 33 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 109
TABLE 34 NORTH AMERICA HOSPITALS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 110
TABLE 35 NORTH AMERICA ASSOCIATED LABS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 111
TABLE 36 NORTH AMERICA INDEPENDENT DIAGNOSTIC LABORATORIES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 111
TABLE 37 NORTH AMERICA DIAGNOSTIC IMAGING CENTER IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 112
TABLE 38 NORTH AMERICA CANCER RESEARCH INSTITUTES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 113
TABLE 39 NORTH AMERICA OTHERS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 113
TABLE 40 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 117
TABLE 41 NORTH AMERICA DIRECT TENDER IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 118
TABLE 42 NORTH AMERICA RETAIL SALES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 119
TABLE 43 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 126
TABLE 44 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 126
TABLE 45 NORTH AMERICA INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 126
TABLE 46 NORTH AMERICA PATHOLOGY-BASED INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 127
TABLE 47 NORTH AMERICA IMAGING INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 127
TABLE 48 NORTH AMERICA BIOPSY INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 127
TABLE 49 NORTH AMERICA CONSUMABLES & ACCESSORIES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 128
TABLE 50 NORTH AMERICA KITS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 128
TABLE 51 NORTH AMERICA REAGENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 128
TABLE 52 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 129
TABLE 53 NORTH AMERICA IMAGING TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 129
TABLE 54 NORTH AMERICA BIOPSY IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 129
TABLE 55 NORTH AMERICA BLOOD TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 130
TABLE 56 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 130
TABLE 57 NORTH AMERICA B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 130
TABLE 58 NORTH AMERICA T-CELL LYMPHOBLASTIC LEUKEMIA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 131
TABLE 59 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 131
TABLE 60 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 131
TABLE 61 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 132
TABLE 62 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 132
TABLE 63 U.S. ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 133
TABLE 64 U.S. INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 133
TABLE 65 U.S. PATHOLOGY-BASED INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 133
TABLE 66 U.S. IMAGING INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 134
TABLE 67 U.S. BIOPSY INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 134
TABLE 68 U.S. CONSUMABLES & ACCESSORIES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 134
TABLE 69 U.S. KITS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 135
TABLE 70 U.S. REAGENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 135
TABLE 71 U.S. ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 135
TABLE 72 U.S. IMAGING TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 136
TABLE 73 U.S. BIOPSY IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 136
TABLE 74 U.S. BLOOD TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 136
TABLE 75 U.S. ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 137
TABLE 76 U.S. B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 137
TABLE 77 U.S. T-CELL LYMPHOBLASTIC LEUKEMIA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 137
TABLE 78 U.S. ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 138
TABLE 79 U.S. ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 138
TABLE 80 U.S. ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 138
TABLE 81 U.S. ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 138
TABLE 82 CANADA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 139
TABLE 83 CANADA INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 139
TABLE 84 CANADA PATHOLOGY-BASED INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 139
TABLE 85 CANADA IMAGING INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 140
TABLE 86 CANADA BIOPSY INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 140
TABLE 87 CANADA CONSUMABLES & ACCESSORIES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 140
TABLE 88 CANADA KITS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 141
TABLE 89 CANADA REAGENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 141
TABLE 90 CANADA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 141
TABLE 91 CANADA IMAGING TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 142
TABLE 92 CANADA BIOPSY IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 142
TABLE 93 CANADA BLOOD TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 142
TABLE 94 CANADA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 143
TABLE 95 CANADA B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 143
TABLE 96 CANADA T-CELL LYMPHOBLASTIC LEUKEMIA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 143
TABLE 97 CANADA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 144
TABLE 98 CANADA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 144
TABLE 99 CANADA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 144
TABLE 100 CANADA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 144
TABLE 101 MEXICO ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 145
TABLE 102 MEXICO INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 145
TABLE 103 MEXICO PATHOLOGY-BASED INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 145
TABLE 104 MEXICO IMAGING INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 146
TABLE 105 MEXICO BIOPSY INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 146
TABLE 106 MEXICO CONSUMABLES & ACCESSORIES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 146
TABLE 107 MEXICO KITS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 147
TABLE 108 MEXICO REAGENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 147
TABLE 109 MEXICO ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 147
TABLE 110 MEXICO IMAGING TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 148
TABLE 111 MEXICO BIOPSY IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 148
TABLE 112 MEXICO BLOOD TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 148
TABLE 113 MEXICO ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 149
TABLE 114 MEXICO B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 149
TABLE 115 MEXICO T-CELL LYMPHOBLASTIC LEUKEMIA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 149
TABLE 116 MEXICO ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 150
TABLE 117 MEXICO ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 150
TABLE 118 MEXICO ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 150
TABLE 119 MEXICO ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 150